QCI Interpret for Oncology
Comprehensive Molecular Tumor Analysis with Alacris Theranostics
247 views
Alacris Theranostics developed the Comprehensive Molecular Tumor Analysis (CMTA), a NGS-based tumor diagnostic test. The test integrates whole exome and transcriptomic sequencing (WES and RNAseq). The test deploys as an end-to-end accredited diagnostic platform from tumor sample uptake (FFPE or frozen) to personalized clinical interpretation reports. CMTA is a tumor-agnostic test that displays a unique molecular view of each sample. CMTA is a useful approach for refractory cancers with complex patterns or tumors of unknown origin.
In this webinar, viewers will:
Learn about the strategy implemented in Alacris’ bioinformatics pipeline to identify cancer-relevant somatic events
Learn how Alacris uses QCI Interpret for Oncology to annotate variants and identify potential therapies
Be eligible for a complimentary QCI Interpret demo and sample report
Related videos
QCI Interpret for Oncology
How to scale-up comprehensive genomic profiling and deliver confident variant interpretations...
As gene panels increase in size, comprehensive genomic profiling and variant...
QCI Interpret for Oncology
Agilent Alissa to QCI Interpret: How can your lab reduce the stress and complexity of...
In 2023, Agilent announced the discontinuation of their Alissa Interpret...
Real-World Insights
Real-World Applications of Clinical Metagenomic Sequencing in Cancer and Infectious Disease...
Clinical metagenomic next-generation sequencing (mNGS), the comprehensive...
QCI Interpret for Oncology
Scale your comprehensive genomic profiling workflow with superior automated variant interpretation
Automating and scaling a comprehensive genomic profiling workflow can be a...